Although ciprofloxacin has been established as the preferred therapy for anthrax, the infrequent nature with which other species are encountered limits recommendations concerning therapy (Table 1). Nonetheless, the threat of bioterrorism has spawned interest in the development of in vitro testing of antimicrobial agents against B. anthracis. The Clinical and Laboratory Standards Institute (CLSI) document M100 addresses the technical issues required for antimicrobial sensitivity testing for Bacillus spp. Most other Bacillus spp. will grow on the media under the conditions recommended for testing the common organisms encountered in clinical specimens (see Chapter 12 for more information regarding validated testing methods), and technical information regarding the testing of the additional species is provided in CLSI document M45, “Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.” Careful evaluation of the organism’s clinical significance must be established before extensive antimicrobial susceptibility testing efforts are undertaken.

Table1. Antimicrobial Therapy and Susceptibility Testing

مواضيع ذات صلة

Drug Resistance

Agents Used to Treat Bacterial Infections

Penicillin- resistant bacteria

المضادات الميكروبية التي ترتبط الى الوحدة الرايبوسومية الكبيرة 50S

المضادات المكروبية التي ترتبط الى الوحدة الرايبوسومية الصغيرة 30S

اختبارات الحساسية للمضادات الحيوية

أوجه الشبه والاختلاف في تركيب جدار الخلية الموجبة - لغرام والسالبة – لغرام التي تؤثر على الحساسية للمضادات الحيوية

الأهداف التي تصيبها المضادات الحيوية في البكتيريا

المضادات الحيوية للبكتيرية Antibacterial Antibiotics

Ethambutol

Pyrazinamide

Isoniazid